IL-35 promotes pancreas cancer growth through enhancement of proliferation and inhibition of apoptosis: Evidence for a role as an autocrine growth factor

Cytokine

Volumn 70, Issue 2, 2014, Pages 126-133

  Nicholl, Michael B ^a   Ledgewood, Chelsea L ^a   Chen, Xuhui ^a,b   Bai, Qian ^a   Qin, Chenglu ^a,b   Cook, Kathryn M ^a   Herrick, Elizabeth J ^a   Diaz Arias, Alberto ^a   Moore, Bradley J ^a   Fang, Yujiang ^c  

^a University of Missouri   (United States)

^b Luohu Hospital   (China)

^c Des Moines University College of Osteopathic Medicine   (United States)

Author keywords

Apoptosis; IL 35; Pancreatic cancer; Proliferation

Indexed keywords

CASPASE 3; CYCLIN B; CYCLIN D; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; DEATH RECEPTOR 4; FAS ANTIGEN; FAS LIGAND; FLICE INHIBITORY PROTEIN; INTERLEUKIN 35; INTERLEUKIN 35 RECEPTOR; INTERLEUKIN RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P27; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; INTERLEUKIN DERIVATIVE; INTERLEUKIN-35, HUMAN; MESSENGER RNA; NEUTRALIZING ANTIBODY; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INHIBITION KINETICS; PANCREAS CANCER; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; CELL SURVIVAL; DRUG EFFECTS; GENETICS; METABOLISM; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANTIBODIES, NEUTRALIZING; APOPTOSIS; AUTOCRINE COMMUNICATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; INTERLEUKINS; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; RECEPTORS, INTERLEUKIN; RNA, MESSENGER;

EID: 84908390756     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.06.020     Document Type: Article

References (42)

1. Nicholl M., Lodge A., Brown I., Sugg S.L., Shilyansky J. Restored immune response to an MHC-II-restricted antigen in tumor-bearing hosts after elimination of regulatory T cells. J Pediatr Surg 2004, 39:941-946.
2. Liyanage U.K., Goedegebuure P.S., Moore T.T., Viehl C.T., Moo-Young T.A., Larson J.W., et al. Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. J Immunother 2006, 29:416-424.
3. Viehl C.T., Moore T.T., Liyanage U.K., Frey D.M., Ehlers J.P., Eberlein T.J., et al. Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. Ann Surg Oncol 2006, 13:1252-1258.
4. Liyanage U.K., Moore T.T., Joo H.G., Tanaka Y., Herrmann V., Doherty G., et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002, 169:2756-2761.
5. Banchereau J., Pascual V., O'Garra A. From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol 2012, 13:925-931.
6. Chaturvedi V., Collison L.W., Guy C.S., Workman C.J., Vignali D.A. Cutting edge: human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J Immunol 2011, 186:6661-6666.
7. Collison L.W., Chaturvedi V., Henderson A.L., Giacomin P.R., Guy C., Bankoti J., et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 2010, 11:1093-1101.
8. Collison L.W., Pillai M.R., Chaturvedi V., Vignali D.A. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J Immunol 2009, 182:6121-6128.
9. Bettini M., Castellaw A.H., Lennon G.P., Burton A.R., Vignali D.A. Prevention of autoimmune diabetes by ectopic pancreatic beta-cell expression of interleukin-35. Diabetes 2012, 61:1519-1526.
10. Seyerl M., Kirchberger S., Majdic O., Seipelt J., Jindra C., Schrauf C., et al. Human rhinoviruses induce IL-35-producing Treg via induction of B7-H1 (CD274) and sialoadhesin (CD169) on DC. Eur J Immunol 2010, 40:321-329.
11. Wirtz S., Billmeier U., McHedlidze T., Blumberg R.S., Neurath M.F. Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis. Gastroenterology 2011, 141:1875-1886.
12. Kochetkova I., Golden S., Holderness K., Callis G., Pascual D.W. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol 2010, 184:7144-7153.
13. Whitehead G.S., Wilson R.H., Nakano K., Burch L.H., Nakano H., Cook D.N. IL-35 production by inducible costimulator (ICOS)-positive regulatory T cells reverses established IL-17-dependent allergic airways disease. J Allergy Clin Immunol 2012, 129(207-215):e201-e205.
14. Wu H., Li P., Shao N., Ma J., Ji M., Sun X., et al. Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF-beta in acute myeloid leukemia. Oncol Lett 2012, 3:1119-1123.
15. Olson B.M., Jankowska-Gan E., Becker J.T., Vignali D.A., Burlingham W.J., McNeel D.G. Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. J Immunol 2012, 189:5590-5601.
16. Long J., Zhang X., Wen M., Kong Q., Lv Z., An Y., et al. IL-35 over-expression increases apoptosis sensitivity and suppresses cell growth in human cancer cells. Biochem Biophys Res Commun 2013, 430:364-369.
17. Fang Y., Wei Y., DeMarco V., Chen K., Sharp G.C., Braley-Mullen H. Murine FLIP transgene expressed on thyroid epithelial cells promotes resolution of granulomatous experimental autoimmune thyroiditis. Am J Pathol 2007, 171:875-887.
18. Fang Y., Sharp G.C., Yagita H., Braley-Mullen H. A critical role for TRAIL in resolution of granulomatous experimental autoimmune thyroiditis. J Pathol 2008, 216:505-513.
19. Fang Y., Yu S., Ellis J.S., Sharav T., Braley-Mullen H. Comparison of sensitivity of Th1, Th2 and Th17 cells to Fas-mediated apoptosis. J Leuk Biol 2010, 87:1019-1028.
20. Fang Y., DeMarco V.G., Nicholl M.B. Resveratrol enhances radiation sensitivity in prostate cancer by inhibiting cell proliferation and promoting cell senescence and apoptosis. Cancer Sci 2012, 103:1090-1098.
21. Fang Y., Herrick E.J., Nicholl M.B. A possible role for perforin and granzyme B in resveratrol enhanced radiosensitivity of prostate cancer. J Androl 2012, 33:752-760.
22. Fang Y., Sharp G.C., Braley-Mullen H. Interleukin-10 promotes resolution of granulomatous experimental autoimmune thyroiditis. Am J Pathol 2008, 172:1591-1602.
23. Fang Y., Yu S., Braley-Mullen H. TGF-β promotes proliferation of thyroid epithelial cells in IFN-γ-/- mice by downregulation of p21 and p27 via AKT pathway. Am J Pathol 2012, 180:650-660.
24. Vignali D.A., Kuchroo V.K. IL-12 family cytokines: immunological playmakers. Nat Immunol 2012, 13:722-728.
25. Collison L.W., Vignali D.A. Interleukin-35: odd one out or part of the family?. Immunol Rev 2008, 226:248-262.
26. Collison L.W., Workman C.J., Kuo T.T., Boyd K., Wang Y., Vignali K.M., et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007, 450:566-569.
27. Collison L.W., Delgoffe G.M., Guy C.S., Vignali K.M., Chaturvedi V., Fairweather D., et al. The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol 2012, 13:290-299.
28. Langrish C.L., McKenzie B.S., Wilson N.J., de Waal Malefyt R., Kastelein R.A., Cua D.J. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 2004, 202:96-105.
29. Hemdan N.Y., Birkenmeier G., Wichmann G. Key molecules in the differentiation and commitment program of T helper 17 (Th17) cells up-to-date. Immunol Lett 2012, 148:97-109.
30. Duvallet E., Semerano L., Assier E., Falgarone G., Boissier M.C. Interleukin-23: a key cytokine in inflammatory diseases. Ann Med 2011, 43:503-511.
31. Awasthi A., Carrier Y., Peron J.P., Bettelli E., Kamanaka M., Flavell R.A., et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol 2007, 8:1380-1389.
32. Li X., Mai J., Virtue A., Yin Y., Gong R., Sha X., et al. IL-35 is a novel responsive anti-inflammatory cytokine-a new system of categorizing anti-inflammatory cytokines. PLoS ONE 2012, 7:e33628.
33. Fang Y., Nicholl M.B. Sirtuin 1 in malignant transformation: friend or foe?. Cancer Lett 2011, 306:10-14.
34. Arlt A., Vorndamm J., Muerkoster S., Yu H., Schmidt W.E., Folsch U.R., et al. Autocrine production of interleukin 1beta confers constitutive nuclear factor kappaB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res 2002, 62:910-916.
35. Prokopchuk O., Liu Y., Henne-Bruns D., Kornmann M. Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions. Br J Cancer 2005, 92:921-928.
36. Bharadwaj U., Marin-Muller C., Li M., Chen C., Yao Q. Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. Carcinogenesis 2011, 32:1013-1024.
37. Kamohara H., Takahashi M., Ishiko T., Ogawa M., Baba H. Induction of interleukin-8 (CXCL-8) by tumor necrosis factor-alpha and leukemia inhibitory factor in pancreatic carcinoma cells: Impact of CXCL-8 as an autocrine growth factor. Int J Oncol 2007, 31:627-632.
38. Formentini A., Prokopchuk O., Strater J., Kleeff J., Grochola L.F., Leder G., et al. Interleukin-13 exerts autocrine growth-promoting effects on human pancreatic cancer, and its expression correlates with a propensity for lymph node metastases. Int J Colorectal Dis 2009, 24:57-67.
39. Ishiko T., Sakamoto K., Yamashita S., Masuda Y., Kamohara H., Mita S., et al. Carcinoma-cells express IL-8 and the IL-8 receptor - their inhibition attenuates the growth of carcinoma-cells. Int J Oncol 1995, 6:119-122.
40. Vignali D.A., Collison L.W., Workman C.J. How regulatory T cells work. Nat Rev Immunol 2008, 8:523-532.
41. Shevach E.M. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009, 30:636-645.
42. Moo-Young T.A., Larson J.W., Belt B.A., Tan M.C., Hawkins W.G., Eberlein T.J., et al. Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer. J Immunother 2009, 32:12-21.